Pfizer und BioNTech
Pfizer und BioNTech geben Update zur Omikron-Variante
08 déc. 2021 06h56 HE | BioNTech SE
Vorläufige Ergebnisse von Laboruntersuchungen zeigen, dass drei Impfdosen des Pfizer-BioNTech COVID-19-Impfstoffs die Omikron-Variante (B.1.1.529) neutralisieren, wohingegen zwei Impfdosen signifikant...
MAKO Medical COVID-19 Sequencing
MAKO Medical Detects Three Cases of COVID-19 Omicron Variant in U.S.
07 déc. 2021 08h45 HE | MAKO Medical
Raleigh, North Carolina, Dec. 07, 2021 (GLOBE NEWSWIRE) -- MAKO Medical Laboratories, a national reference laboratory and leader in COVID-19 testing, today announced that it has detected three cases...
Vir Biotechnology to Host a Call on Sotrovimab’s Retained Activity Against the Omicron SARS-CoV-2 Variant
07 déc. 2021 03h55 HE | Vir Biotechnology, Inc.
SAN FRANCISCO, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) announced that Management will host a conference call at 8:30 am ET, Tuesday, December 7, 2021, to discuss new...
Preclinical Studies Demonstrate Sotrovimab Retains Activity Against the Full Combination of Mutations in the Spike Protein of the Omicron SARS-CoV-2 Variant
07 déc. 2021 03h48 HE | Vir Biotechnology, Inc.
 – New preclinical findings generated through in vitro testing of sotrovimab againstthe complete pseudo-virus updated to bioRxiv – Data build on promising signal published last week, underscoring the...
iHealth Statement on the COVID-19 Omicron Variant and Its At-Home Test Kit's Effectiveness
02 déc. 2021 17h37 HE | iHealth Labs Inc
SUNNYVALE, Calif., Dec. 02, 2021 (GLOBE NEWSWIRE) -- iHealth Labs Inc., a leader in the design and manufacturing of consumer-friendly, mobile personal healthcare products, issued the following...
Codiak’s Engineered Exosomes Promote T Cell and Antibody Responses to SARS-CoV-2 in vivo, Supporting the Potential for a Broadly Protective Pan-Beta Coronavirus and Variant Vaccine
02 déc. 2021 08h30 HE | Codiak BioSciences, Inc.
CAMBRIDGE, Mass., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based...
Achiko Logo cropped.jpg
Achiko’s Position on Omicron Variant
02 déc. 2021 07h30 HE | Achiko AG
The chemical mode of action of AptameX, Achiko's rapid Covid-19 test, strongly suggests that Omicron can be detected as reliably as any other Covid-19 variant known to dateAchiko’s highly effective,...
Preclinical Data Demonstrate Sotrovimab Retains Activity Against Key Omicron Mutations, New SARS-CoV-2 Variant
02 déc. 2021 02h07 HE | Vir Biotechnology, Inc.
 – Preclinical data demonstrate sotrovimab, authorized in multiple countries around the world, retains activity against all tested variants of concern, including key mutations of Omicron – – Data to...
Prof Felicity Burt
The new Omicron variant: What we know and don’t know
01 déc. 2021 05h56 HE | University of the Free state
Bloemfontein, Dec. 01, 2021 (GLOBE NEWSWIRE) -- Even though not much is yet known about the new COVID-19 variant, Omicron, the presence of a high number of mutations – more than 30 – in the spike...
First Wave BioPharma Announces Independent Data Monitoring Committee Provides Positive Interim Safety Assessment for Part 2 COVID-19 RESERVOIR Clinical Trial of Niclosamide for the Treatment of Gastrointestinal Infections
30 nov. 2021 07h00 HE | First Wave BioPharma, Inc.
BOCA RATON, Fla., Nov. 30, 2021 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...